Dapagliflozin in Heart Failure: an evidence-based approach to cost and benefit

Abstract

Heart failure is one of the most critical clinical challenges today, with high morbidity and mortality and significant burdens on healthcare systems. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor initially indicated for type 2 diabetes, has shown remarkable cardiovascular benefits even in non-diabetic patients. This study reviews the literature to assess the cost-benefit relationship of dapagliflozin in heart failure, considering clinical evidence and economic analyses. Trials such as DAPA-HF and DELIVER demonstrate the drug's effectiveness in reducing hospitalizations and cardiovascular mortality, as well as improving renal function. Although the initial cost is high, studies indicate long-term savings, making it cost-effective, particularly in public healthcare settings. Incorporating dapagliflozin into therapeutic protocols can optimize resource allocation and improve clinical outcomes, especially in low- and middle-income countries.